You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. TOPIC 372: DEVELOPMENT AND VALIDATION OF CANINE SCFVS FOR PRE-CLINICAL DEVELOPMENT OF TARGETED THERAPEUTICS

    SBC: Vetigenics LLC            Topic: NCI

    The goal of this SBIR is to provide proof of concept of Vetigenicscanine derived scFv phage display platform for rapidcost effective production of highly versatilecanine derived scFvsscFvs against CDCDand CTLAthree high valueimmunological molecules being targeted by antibody based strategies in human cancer immunotherapywill be isolatedSelected scFvs will be sequenced and binding affinities determ ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.

    SBC: DeLeon, Augustina S            Topic: NIAAA

    Technology validation study of a wearable NIR spectrometer to quantify BAC in real time

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Electrochemical aptasensor for Anti-Tuberculosis antibiotic quantification

    SBC: GUILD ASSOCIATES INC            Topic: NIAID

    Specific AimsIn Phase I of this SBIRwe will complete three specific aimssynthesize stable combination adjuvant formulations that are compatible with an HVLP antigenidentify the combination adjuvant properties that augment the safe and durable immunity to Handdemonstrate the superior protective benefit of the new combination adjuvant over existing adjuvant solutions for pandemic influenza vaccinesI ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Antibody Fragments to Improve HIV gp120 Protein Production

    SBC: ABZYME THERAPEUTICS LLC            Topic: NIAID

    Camelid single domain antibody fragmentsVHHpossess a number of distinctive features including a small sizean elevated stabilityand an ability to recognize epitopes non accessible for conventional antibodiesBesides common research and immunotherapy applicationscamelid VHHs are also used as co crystallization chaperonesprotein aggregation controllers and enzyme activity tunersIn this proposalwe wish ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 386: PROOF OF CONCEPT FOR A TOPICAL MEK INHIBITOR AS A CHEMOPREVENTIVE AGENT FOR SQUAMOUS CELL CARCINOMA IN HIGH RISK ORGAN TRANSPLANT PATIENTS

    SBC: NFlection Therapeutics, Inc.            Topic: NCI

    Solid organ transplantation can be life savingHoweverimmunosuppression necessary to prevent rejection increases the incidence of cutaneous squamous cell carcinomacSCCfoldCurrent treatments for solid organ transplant recipientsSOTRsare largely surgicalwhich can be disfiguring and impact quality of lifeThere is a huge need for a safe and effective chemoprevention agent for cSCC in SOTRsThe RAF MEK E ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 386: NOVEL ORALLY BIOAVAILABLE PDE-CATENIN INHIBITOR CONCENTRATES IN LUNG FOR CANCER CHEMOPREVENTION

    SBC: ADT Pharmaceuticals, LLC            Topic: NCI

    This application is based on ADT Pharmaceuticalsdiscoveries thatthe cGMP degrading phosphodiesterase isozymephosphodiesteraseAPDEis overexpressed during early stages of tumorigenesisgenetic knockdown of PDEresults in selective apoptosis of tumor cells by activating cGMP PKG signalingandsmall molecule inhibitors of PDEinduce apoptosis by PKG phosphorylation of oncogeniccateninthereby suppressing Tc ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 396- IMAGING FOR CANCER IMMUNOTHERAPIES-MOONSHOT

    SBC: COLUMBUS NANOWORKS, INC.            Topic: NCI

    In vivo imaging of cells labeled with fluorescent nanodiamondsFNDsis a new way of monitoring immune cells during cancer immunotherapyFNDs are non toxicinfinitely photostable nanomaterials that are easily conjugated with antibodiesand emit fluorescence in the near infrared spectral regionIn this Phase I SBIRwe will use a murine melanoma model and outline a plan to use FNDs for imaging immunosupress ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 389- INTELLIGENT SOFTWARE FOR RADIATION THERAPY PLANNING

    SBC: RADIASOFT LLC            Topic: NCI

    Besides surgeryradiotherapy is the most effective treatment modality for localized prostate cancerThe success of radiotherapy stems from the exploit of a therapeutic window in tumor response and normal tissue tolerance which maximizes the chance of sterilizing the tumor while sparing the surrounding normal tissue from severe damageThis requires an accurate and individualized radiation dose distrib ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Strong protections, tracking, diversion detection, and deactivation of opioid medications in the hospital and related caregiving settings.

    SBC: Curazel LLC            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop a comprehensive approach to allow hospitals gain control of their opioid medicationsThe Contractor approach is totrack opioids from the pharmacy to the patienttrack the amount given to the patientand for opioid waste to track it back to the pharmacybetter administer opioids to patients that offe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. STING Inhibitor Discovery for Rare and Common Autoimmune Diseases

    SBC: DISCOVERYBIOMED, INC.            Topic: NIAID

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Nitor TherapeuticsIncNitorProject Summary Abstract The over arching commercial goal for this Nitor TherapeuticsIncNitorand DiscoveryBioMedIncDBMcollaboration is to discover and validate Stimulator of Interferon Genes orSTINGinhibitor ligands in a novel high throughput screeningHTSand validation based Critical Path of bioassaysAberr ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government